Literature DB >> 7835635

Gender and test dependence of a type of kappa mediated stress induced analgesia in mice.

L Menendez1, F Andrés-Trelles, A Hidalgo, A Baamonde.   

Abstract

1. In male mice, 80 inescapable footshocks (S-80) induce analgesic responses measured by the tail flick test that are blocked by naloxone and the kappa opioid antagonist, nor-binaltorphimine. We now study the nociceptive responses, induced after this particular stress, measured by the writhing test, the tail immersion test and a high intensity tail immersion test both in male and female mice. 2. In stressed males, analgesic responses are seen in all the nociceptive tests. Naloxone (10 mg/kg) does not prevent them. 3. In stressed females, in contrast with males, no analgesia is produced in the tail flick test. The writhing test and the tail immersion test registered analgesic responses that were not prevented by naloxone (10 mg/kg). 4. We conclude that only the antinociceptive kappa opioid mediated component of the stress we study is strongly dependent on gender, in contrast to other types of analgesia triggered by the same stress.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7835635     DOI: 10.1016/0306-3623(94)90094-9

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  3 in total

1.  Identification of a sex-specific quantitative trait locus mediating nonopioid stress-induced analgesia in female mice.

Authors:  J S Mogil; S P Richards; L A O'Toole; M L Helms; S R Mitchell; B Kest; J K Belknap
Journal:  J Neurosci       Date:  1997-10-15       Impact factor: 6.167

Review 2.  Sex, gender, and pain: an overview of a complex field.

Authors:  Robert W Hurley; Meredith C B Adams
Journal:  Anesth Analg       Date:  2008-07       Impact factor: 5.108

3.  Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist.

Authors:  A M W Taylor; K W Roberts; A A Pradhan; H A Akbari; W Walwyn; K Lutfy; F I Carroll; C M Cahill; C J Evans
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.